… pharmacokinetic and pharmacodynamic variability 3,4 and to … monitoring using liquid
chromatography-tandem mass spectrometry pharmacodynamic therapeutic drug monitoring …

… efficacy of DOACs is less robust, and that in those with BMI >50Kg/m 2 , therapeutic drug
monitoring or switching to a vitamin K antagonist may be a reasonable approach [Citation123]. …

… laboratory monitoring due to their unpredictable pharmacokinetics and pharmacodynamics.
… requiring some form of dose tailoring or therapeutic drug monitoring.[1] They notably show …

… While multiple patient characteristics impact the pharmacodynamics and pharmacokinetics
… drug exposure and outcomes is a critical step to assess the possible value of drug monitoring…

… adults that increases the risk of drug-drug interactions (DDIs), both pharmacokinetic (PK)
and pharmacodynamic (PD). Direct oral anticoagulants (DOACs) are frequently prescribed in …

… Apixaban, a direct inhibitor of factor Xa, exhibits consistent pharmacokinetic and
pharmacodynamic characteristics across a diverse patient population, encompassing individuals of …

The direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban, and edoxaban,
are becoming the most commonly prescribed drugs for preventing ischemic stroke in …

… Direct oral anticoagulants (DOACs) describe a group of drugs that have emerged over the last
… These drugs do not require routine therapeutic monitoring since they were developed and …

… In samples collected as part of routine care DOAC drug … Anticoagulant intensity at first
presentation and drug half-life (… on anticoagulant intensity at first presentation and drug half-…

… a complicated relationship between pharmacokinetics (PKs) and pharmacodynamics (PDs). …
Routine monitoring of coagulation to guide direct oral anticoagulant therapy is generally not …